List of Excipients in Branded Drug MAXITROL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	MAXITROL	neomycin sulfate, polymyxin b sulfate and dexamethasone	0065-0631	LANOLIN
Alcon Laboratories Inc	MAXITROL	neomycin sulfate, polymyxin b sulfate and dexamethasone	0065-0631	METHYLPARABEN
Alcon Laboratories Inc	MAXITROL	neomycin sulfate, polymyxin b sulfate and dexamethasone	0065-0631	PETROLATUM
Alcon Laboratories Inc	MAXITROL	neomycin sulfate, polymyxin b sulfate and dexamethasone	0065-0631	PROPYLPARABEN
Novartis Pharmaceuticals Corporation	MAXITROL	neomycin sulfate, polymyxin b sulfate and dexamethasone	0078-0771	LANOLIN

Maxitrol Excipient Strategy and Commercial Opportunities

Last updated: September 1, 2026

Maxitrol is a prescription ophthalmic combination of dexamethasone, neomycin sulfate, and polymyxin B sulfate. Its commercial value is no longer protected primarily by exclusivity. The strongest opportunities are formulation improvements, preservative reduction, unit-dose delivery, suspension performance, and differentiated manufacturing controls.

The product has two relevant dosage forms:

Product	Active ingredients	Dosage form	Principal excipient strategy
Maxitrol ophthalmic suspension	Dexamethasone 1 mg/mL; neomycin equivalent to 3.5 mg/mL; polymyxin B 6,000 units/mL	Multidose sterile suspension	Wetting, viscosity control, isotonicity, antimicrobial preservation and pH adjustment
Maxitrol ophthalmic ointment	Dexamethasone, neomycin and polymyxin B	Sterile ophthalmic ointment	Mineral oil and white petrolatum base

The suspension is the more attractive platform for innovation because it must maintain uniform dosing after shaking, support chemical stability for three active ingredients, remain sterile during repeated use, and minimize ocular irritation. The ointment has a simpler excipient system but faces greater patient-acceptance and vision-blurring limitations.[1]

What excipients are used in Maxitrol ophthalmic products?

The Maxitrol ophthalmic suspension uses polysorbate 20, hypromellose, sodium chloride, benzalkonium chloride, and hydrochloric acid and/or sodium hydroxide for formulation adjustment. The ointment uses mineral oil and white petrolatum.[1]

Maxitrol suspension excipient functions

Excipient	Functional role	Commercial relevance
Polysorbate 20	Wetting and dispersion of suspended drug particles	Helps reduce aggregation and improves redispersion
Hypromellose	Suspending and viscosity-enhancing agent	Supports dose uniformity and residence time
Sodium chloride	Tonicity adjustment	Helps align the formulation with ocular tolerability requirements
Benzalkonium chloride	Multidose antimicrobial preservative	Supports in-use sterility but creates preservative-free and tolerability opportunities
Hydrochloric acid/sodium hydroxide	pH adjustment	Controls stability, solubility and ocular comfort

The excipient system is functional rather than highly differentiated. A generic competitor can generally pursue the same therapeutic combination with a different inactive-ingredient profile if it demonstrates pharmaceutical equivalence, bioequivalence where applicable, product quality and acceptable safety.

How does the Maxitrol formulation work technically?

Maxitrol suspension presents a difficult formulation problem because the active ingredients have different physical and chemical properties. Dexamethasone is a corticosteroid with limited aqueous solubility. Neomycin sulfate and polymyxin B sulfate are water-soluble antibiotic salts. A single liquid formulation must maintain compatibility between suspended and dissolved components.

Hypromellose increases viscosity and reduces sedimentation. Its concentration must remain low enough to permit easy dispensing and rapid redispersion but high enough to maintain dose uniformity between the first and last doses. Excessive viscosity can impair drop formation, increase residual product in the bottle and reduce patient adherence.

Polysorbate 20 improves particle wetting. Its level must be controlled because surfactants can contribute to ocular irritation, interact with container surfaces, or alter the physical stability of suspended particles.

Benzalkonium chloride provides multidose preservation. Its use creates a clear product-development pathway because repeated exposure to benzalkonium chloride can be undesirable for patients with ocular-surface disease or frequent dosing requirements. FDA labeling for ophthalmic products recognizes preservative exposure as a formulation and tolerability consideration.[1,2]

What excipient strategies could improve Maxitrol?

The highest-value strategies are preservative reduction, preservative-free packaging, improved suspension redispersion, and better ocular residence time.

Preservative-free Maxitrol suspension

A preservative-free product could be delivered through:

• Single-dose sterile ampoules
• Multidose preservative-free valve bottles
• Blow-fill-seal containers
• Metered-dose ophthalmic pumps
• Sterile unit-dose droppers

The commercial advantage would be strongest in postoperative patients, chronic ocular-surface disease, contact-lens-related sensitivity and patients receiving multiple preserved ophthalmic medicines.

The principal barriers are manufacturing complexity, container-closure validation, microbial ingress control, dose accuracy and higher packaging cost. A preservative-free product would need a credible clinical and usability rationale because the existing product is inexpensive and generic competition is established.

Improved redispersion

A differentiated suspension could use optimized particle size, surface treatment, polymer concentration or a revised wetting system to reduce settling and improve redispersion. The product objective would be consistent drug delivery without vigorous shaking.

Potential quality attributes include:

• Sedimentation rate
• Ease and speed of redispersion
• Particle-size distribution
• Dose uniformity throughout bottle life
• Drop size
• Viscosity
• Extractable and leachable profile
• Chemical stability after opening

A product that visibly settles less rapidly could improve patient confidence, but the label would still need appropriate shaking instructions unless the formulation demonstrates uniform dosing without shaking.

Lower-viscosity, residence-enhancing suspension

The formulation could use a polymer system that provides modest viscosity at dispensing but increases residence time after contact with the ocular surface. Candidate approaches include optimized cellulose derivatives, carbomer systems or mucoadhesive polymers.

The development risk is ocular tolerability. A thicker formulation can cause blurred vision, sticky sensation, slower drop formation and reduced adherence. The target should be controlled residence time rather than maximum viscosity.

Reduced-irritation preservative system

A reformulated product could replace benzalkonium chloride with a less aggressive preservative system, provided the preservative is compatible with the active ingredients and the container. Options may include oxidative preservatives, ionic systems or preservative-free delivery.

The opportunity is commercially meaningful only if the revised product supports a defensible clinical claim, such as improved ocular-surface tolerability or reduced preservative exposure. A simple substitution without clinical differentiation would face rapid generic price pressure.

What formulations are protected by Maxitrol patents?

Maxitrol is an old combination product, and its principal commercial protection does not depend on a current composition-of-matter patent. FDA Orange Book records for legacy Maxitrol products do not indicate a meaningful current patent barrier comparable to a recently approved branded ophthalmic medicine.[3]

Protection category	Maxitrol position
Active-ingredient patent	Expired or commercially irrelevant
New chemical entity exclusivity	Not applicable
Formulation patent	No material current barrier identified in the Orange Book record
Method-of-use patent	No material current barrier identified
Pediatric exclusivity	No current strategic relevance
Trademark	Maxitrol brand remains commercially relevant
Regulatory exclusivity	No current exclusivity expected to block approved generics

A new formulation could receive patent protection if it claims a genuinely novel combination of excipients, particle engineering, preservative-free container, delivery mechanism, manufacturing process or stability profile. A patent directed only to substituting one conventional excipient for another would face substantial validity and obviousness risk.

When does Maxitrol lose exclusivity?

Maxitrol has already lost the exclusivity associated with its original approval. Generic versions of neomycin, polymyxin B and dexamethasone ophthalmic products are commercially available, and the combination is treated as a mature multisource prescription product.

The relevant commercial question is therefore not the date of original patent expiry. It is whether a new formulation can obtain independent protection through:

1. A novel excipient composition.
2. A proprietary preservative-free delivery system.
3. A differentiated container-closure system.
4. A new dosage form.
5. A new method of use supported by clinical evidence.
6. A manufacturing process that produces a non-obvious stability or uniformity advantage.

A reformulated product would not restore exclusivity to the existing Maxitrol formulation. It would require its own approved application and its own patent strategy.

What is the Orange Book status of Maxitrol?

The FDA Orange Book identifies approved drug products and, where applicable, listed patents and exclusivity. Maxitrol is associated with legacy ophthalmic suspension and ointment approvals rather than an active innovative-drug exclusivity position.[3]

The commercial implications are significant:

• Generic applicants can use the abbreviated new drug application pathway.
• The incumbent cannot rely on remaining NCE exclusivity.
• Formulation differences must be justified through product quality, safety, labeling and equivalence requirements.
• An improved product may be marketed as a separate branded formulation if it has a distinct approved application and defensible clinical or usability advantages.

The Orange Book does not by itself establish whether a particular generic applicant has filed a Paragraph IV certification or whether a settlement exists. Paragraph IV risk depends on the patents listed against the relevant reference product and the certifications filed by each ANDA applicant.

Which companies are challenging Maxitrol?

Maxitrol competes with generic manufacturers of neomycin sulfate, polymyxin B sulfate and dexamethasone ophthalmic suspension and ointment. The market includes established generic ophthalmic manufacturers, contract manufacturers and branded ophthalmic companies with portfolios in anti-infective and corticosteroid products.

A reliable public assessment of individual Paragraph IV challengers requires applicant-level ANDA records and current litigation-docket review. The principal competitive threat is broader than a single challenger: multiple manufacturers can enter a mature ophthalmic combination market once approval requirements are met.

The competitive landscape includes:

Competitor type	Threat to Maxitrol	Opportunity for a new entrant
Conventional generic suspension	Price erosion	Low-cost supply and reliable manufacturing
Generic ointment	Substitution in postoperative care	Improved tolerability or less visual blurring
Separate antibiotic and steroid products	Prescriber flexibility	Combination convenience and adherence
Newer ophthalmic steroid products	Clinical substitution	Better safety, dosing frequency or residence time
Preservative-free combinations	Ocular-surface differentiation	Premium branded positioning

What generic entry risks exist for Maxitrol?

Generic entry risk is high because the active ingredients are established, the formulation is conventional and the product has no meaningful remaining exclusivity barrier.

Price erosion

The standard suspension and ointment are vulnerable to multi-source pricing. A new entrant using the same general formulation architecture would likely compete on:

• Wholesale acquisition cost
• Contracting
• Supply reliability
• Pharmacy availability
• Hospital and ambulatory-surgery contracts
• Packaging convenience

A premium price requires a demonstrable advantage, such as preservative-free delivery, lower dosing frequency, superior redispersion or improved ocular-surface tolerability.

Substitution risk

Prescribers may use separate antibiotic and corticosteroid products when they want to adjust treatment duration or avoid unnecessary antibiotic exposure. Combination products retain convenience value but may be less attractive where antimicrobial stewardship is a priority.

Supply-chain risk

Ophthalmic products require sterile manufacturing, specialized filling equipment and validated container-closure systems. Manufacturing capacity can therefore create a barrier even when patents do not. Suppliers must control particulate matter, fill volume, microbial limits, container integrity and extractables and leachables.

What manufacturing and IP barriers affect Maxitrol opportunities?

The most defensible IP position would combine formulation claims with process and device claims. A practical patent estate could cover:

• Specific polymer and surfactant ratios
• Particle-size distribution
• Surface-modified dexamethasone particles
• Preservative-free multidose dispensing
• In-use microbial protection
• Defined redispersion performance
• Low-irritation preservative systems
• Container-closure compatibility
• Sterilization or aseptic-processing methods
• Stability after repeated opening and dosing

Manufacturing know-how may be more valuable than patent breadth. Critical trade secrets could include dispersion order, mixing energy, homogenization parameters, active-ingredient addition sequence, hold times, filtration strategy and filling conditions.

A formulation patent should connect the excipient composition to measurable performance. Claims supported only by ingredient lists may be vulnerable unless the composition produces an unexpected stability, uniformity or tolerability result.

How does Maxitrol compare with commercial alternatives?

Attribute	Maxitrol suspension	Maxitrol ointment	Preservative-free reformulation concept
Patient convenience	High	Moderate	High if packaging is simple
Visual impact	Lower than ointment	More blurring risk	Depends on vehicle
Preservative exposure	Present	Usually lower preservative complexity	Reduced or eliminated
Manufacturing complexity	Moderate to high	Moderate	High
Generic price pressure	High	High	Lower if differentiated
Patent opportunity	Limited for legacy product	Limited for legacy product	Stronger if technology is novel
Regulatory burden	Established pathway	Established pathway	Higher due to new device and sterility controls

Are biosimilars a risk for Maxitrol?

No. Maxitrol is a small-molecule and peptide-antibiotic combination ophthalmic product, not a biologic. Biosimilar competition is not the relevant entry pathway.

The applicable competitive pathways are generic ANDAs, 505(b)(2) applications for materially changed formulations, and potentially a new drug application for a clinically differentiated product. A preservative-free or device-enabled reformulation may fit a 505(b)(2) strategy if the sponsor can rely partly on existing findings while establishing the changed formulation and delivery system.[4]

Are there licensing opportunities for Maxitrol excipient technology?

The strongest licensing opportunity would involve a platform rather than the legacy Maxitrol formulation. Potential licensors include:

• Preservative-free ophthalmic container developers
• Ophthalmic polymer and mucoadhesive suppliers
• Sterile blow-fill-seal manufacturers
• Multidose valve-bottle companies
• Particle-engineering specialists
• Contract development and manufacturing organizations

A license should be tied to measurable performance, such as extended in-use stability, validated microbial protection, reduced preservative exposure, improved redispersion or reduced dosing frequency. A license covering only a conventional excipient substitution would have limited negotiating value.

No major publicly disclosed licensing transaction is required to commercialize a Maxitrol-compatible formulation. The more likely model is a sponsor-led development program supported by contract manufacturing, excipient licensing or a device partnership.

What is the commercial opportunity for a new Maxitrol formulation?

The opportunity is a premium, differentiated ophthalmic anti-infective corticosteroid rather than another commodity generic.

The most attractive concepts are:

1. Preservative-free unit-dose suspension for postoperative and ocular-surface-sensitive patients.
2. Preservative-free multidose bottle with validated microbial protection.
3. Improved-redispersion suspension with consistent dosing.
4. Lower-blur ointment or gel technology.
5. Reduced-frequency dosing enabled by longer ocular residence.
6. Hospital-focused packaging with tamper evidence and dose tracking.
7. Separate pediatric or low-volume delivery formats, subject to clinical and regulatory support.

Revenue exposure for the incumbent is likely concentrated in brand retention, physician familiarity, distribution and institutional contracts rather than patent-protected pricing. A new entrant can capture value only by avoiding direct commodity competition or by achieving a lower cost of sterile manufacture.

Key Takeaways

• Maxitrol combines dexamethasone, neomycin sulfate and polymyxin B sulfate in ophthalmic suspension and ointment dosage forms.
• The suspension depends on hypromellose, polysorbate 20, sodium chloride and benzalkonium chloride for physical stability, tonicity and multidose preservation.
• The product has no meaningful current exclusivity barrier comparable to a recently approved branded ophthalmic drug.
• Generic entry risk is high for conventional suspension and ointment products.
• Preservative-free delivery, improved redispersion, reduced ocular irritation and advanced packaging offer the strongest commercial opportunities.
• New patent value would come from measurable formulation, device or manufacturing performance, not from the legacy Maxitrol composition.
• Biosimilars are irrelevant; generic ANDA and 505(b)(2) pathways are the main competitive routes.
• Sterile manufacturing, container-closure integrity and in-use microbial control are major commercial barriers.

FAQs

Can a preservative-free Maxitrol product receive new patent protection?

Yes. Protection could cover a novel excipient system, preservative-free multidose container, microbial-control mechanism, particle-engineering method or manufacturing process. The claims must demonstrate novelty and non-obvious performance.

Could a Maxitrol reformulation qualify for a 505(b)(2) application?

Potentially. A materially changed vehicle, preservative system, dosage form or delivery device may support a 505(b)(2) application if the sponsor can bridge to existing safety and efficacy information while generating data for the changes.[4]

Which Maxitrol excipient creates the clearest differentiation opportunity?

Benzalkonium chloride creates the clearest commercial opportunity because a preservative-free or lower-irritation alternative could target patients with ocular-surface sensitivity. The replacement must preserve sterility and active-ingredient stability.

Is Maxitrol ointment easier to manufacture than the suspension?

Generally, yes. The ointment has a simpler vehicle system, but it has greater patient-acceptance limitations, including visual blurring and less convenient administration.

Can a new manufacturer compete with Maxitrol without owning patents?

Yes. A manufacturer can enter through an approved generic or reformulated product if it satisfies FDA requirements. Patent ownership becomes more important for premium positioning, device differentiation and protection against follow-on competitors.

References

1. DailyMed. (2024). Maxitrol: Neomycin sulfate, polymyxin B sulfate, and dexamethasone ophthalmic suspension and ointment prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2022). Ophthalmic drug products for topical administration: Product quality considerations. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.